Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Frank Stein who wrote (53)	12/5/1997 9:07:00 AM
From: Henry Niman	Respond to of 643

The rexinoid/PPAR connection was discussed at length at the recent Robertson Stephens conference. I expect LLY to move very quickly and forcefully in this area with clinical trials launched using Rexinoids (Targretin is the first one) for the treatment and prevention of type II diabetes. Monotherapy will be targeted for prevention and early disease. Combination therapy including TZDs (like Rezulin of 2nd generation compounds of SBH, Takeda, or LGND as well as sulfanylureas, and Metformin), will also be vigorously explored. I suspect that LLY will be looking toward rexinoids to fill their pipeline, which will need some serious work when blockbusters go off patent in 2002 and 2003. The nice review of Retinoids and Rexinoids, including relationships with ALRI and LLY can be found at: recap.com